A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 31/275 (2006.01) A61K 9/20 (2006.01) A61K 9/22 (2006.01) A61K 31/277 (2006.01)
Patent
CA 2214100
Verapamil depot drug formulations include the pharmaceutical itself and a three component release rate controlling matrix composition. The three components of the matrix composition are (1) an alginate component, such as sodium alginate, (2) an enteric polymer component, such as methacrylic acid copolymer, and (3) a pH independent gelling polymer, such as hydroxypropyl methylcellulose or polyethyleneoxide. The drug release rate can be adjusted by changing the amount of one or more of these components of the composition.
Préparations de Vérapamil sous forme de médicaments à effet retard comportant le produit pharmaceutique proprement dit et une matrice à trois composants régulant la vitesse de libération. Lesdits composants sont: (1) un alginate tel que l'alginate de sodium, (2) un polymère entérique tel qu'un copolymère de l'acide méthacrylique, et (3) un polymère gélifiant indépendant du pH tel que l'hydroxypropylméthylcellulose ou l'oxyde de polyéthylène. La vitesse de libération peut s'ajuster en modifiant la quantité de l'un ou plusieurs des composants de la composition.
Pinnamaraju Prasad
Zhang Guohua
Hallmark Pharmaceuticals Inc.
Sim & Mcburney
Teva Women's Health Inc.
LandOfFree
Sustained release formulation containing three different... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Sustained release formulation containing three different..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Sustained release formulation containing three different... will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1544301